SHS Capital
VC Fund
Tübingen, Germany
SHS Capital is a VC fund in Tübingen focused on Health Care and Medical Device. SHS is an independent private equity company. Their focus is on investments in the MedTech, Life Sciences, Diagnostics, and Digital Health sectors.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 57%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries SHS Capital invests in
Stages SHS Capital invests in
Countries SHS Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $4.9M–$60M
- Series C
- $6.6M–$14M
Investment Focus
Industry
- Health Care 17 (39%)
- Medical Device 14 (32%)
- Medical 12 (27%)
- Manufacturing 11 (25%)
- Biotechnology 10 (23%)
Stage
- Funding Round 15 (34%)
- Series B 5 (11%)
- Series C 5 (11%)
- Series A 4 (9%)
- Venture - Series Unknown 4 (9%)
Country
- Germany 14 (32%)
- Switzerland 7 (16%)
- France 2 (5%)
- Austria 2 (5%)
- The Netherlands 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andre Zimmermann
Partner
|
Partner | Total investments: 2 | Find email | |
Sascha Alilovic
Partner
|
Partner | Total investments: 5 | Find email | |
Bernhard Schirmers
Managing partner
|
Managing partner | Total investments: 2 | Find email | |
David Wehner
Senior Investment manager
|
Senior Investment manager | Total investments: 1 | Find email | |
Federico Bursgens
Limited Partner
|
Limited Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Arzneimittelwerk Warngau
|
Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. WilfriedFischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany. | Secondary Market / Mar 05, 2026 | |
Salvia BioElectronics
|
Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M / Series B / May 27, 2025 | |
Develco Pharma Schweiz
|
Develco Pharma Schweiz is pharmaceutical manufacturing company produce formulations of drugs, health care, medicine. | $11M / Oct 07, 2024 | |
MESI Medical
|
We help clinicians provide better medical assessment in less time! The MESI mTABLET is an FDA/CE marked predictive medical assessment platform for ambulatory healthcare with extensive AI and marketplace capabilities. | $19.7M / Venture - Series Unknown / Jun 22, 2023 | |
Simulands
|
Simulands improve patient outcomes through simulation-based medical training. Simulands solutions are more practical, cost effective, and ethical versus traditional methods. | $10.6M / Seed / Mar 02, 2023 | |
Dr.Dropin
|
Dr.Dropin an accessible and modern private health service that offers the vast majority of medical services at a fixed price. | $20.8M / Venture - Series Unknown / Apr 21, 2022 | |
PathoQuest
|
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $15.9M / Series B / Nov 09, 2021 | |
|
PathoQuest
|
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $17.4M / Series B / Nov 09, 2021 | |
Incision
|
Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. | Series A / May 27, 2021 | |
|
Incision
|
Incision is a developer of a medical education platform built to offer a standardized method of how to perform a procedure in practical steps and sub-steps. | $5.5M / Series A / May 24, 2021 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does SHS Capital invest in?
SHS Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Funding Round and Series B stage. Most of the 44 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SHS Capital's check size?
SHS Capital typically joins rounds of $4.9M–$60M at Series B and $6.6M–$14M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SHS Capital participates in.
How do I contact SHS Capital?
Public channels for SHS Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SHS Capital?
The team at SHS Capital includes Andre Zimmermann (Partner), Sascha Alilovic (Partner) and Bernhard Schirmers (Managing partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
